- Home
- VTYX vs MAPS Comparison
VTYX vs MAPS Comparison
Compare VTYX & MAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- MAPS
- Stock Information
- Founded
- VTYX 2018
- MAPS 2008
- Country
- VTYX United States
- MAPS United States
- Employees
- VTYX N/A
- MAPS N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- MAPS Computer Software: Prepackaged Software
- Sector
- VTYX Health Care
- MAPS Technology
- Exchange
- VTYX Nasdaq
- MAPS Nasdaq
- Market Cap
- VTYX 154.9M
- MAPS 134.9M
- IPO Year
- VTYX 2021
- MAPS N/A
- Fundamental
- Price
- VTYX $1.61
- MAPS $1.39
- Analyst Decision
- VTYX Buy
- MAPS Strong Buy
- Analyst Count
- VTYX 4
- MAPS 1
- Target Price
- VTYX $11.33
- MAPS $2.61
- AVG Volume (30 Days)
- VTYX 1.3M
- MAPS 1.4M
- Earning Date
- VTYX 03-04-2025
- MAPS 11-12-2024
- Dividend Yield
- VTYX N/A
- MAPS N/A
- EPS Growth
- VTYX N/A
- MAPS N/A
- EPS
- VTYX N/A
- MAPS N/A
- Revenue
- VTYX N/A
- MAPS $183,311,000.00
- Revenue This Year
- VTYX N/A
- MAPS N/A
- Revenue Next Year
- VTYX N/A
- MAPS $5.99
- P/E Ratio
- VTYX N/A
- MAPS N/A
- Revenue Growth
- VTYX N/A
- MAPS N/A
- 52 Week Low
- VTYX $1.57
- MAPS $0.70
- 52 Week High
- VTYX $11.48
- MAPS $1.65
- Technical
- Relative Strength Index (RSI)
- VTYX 34.49
- MAPS 51.53
- Support Level
- VTYX $1.57
- MAPS $1.31
- Resistance Level
- VTYX $1.78
- MAPS $1.47
- Average True Range (ATR)
- VTYX 0.10
- MAPS 0.08
- MACD
- VTYX -0.00
- MAPS 0.00
- Stochastic Oscillator
- VTYX 10.26
- MAPS 55.00
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.